82 results on '"Postuma R"'
Search Results
2. Concerns with the new biological research criteria for synucleinopathy - Authors' reply.
- Author
-
Lang AE, Höglinger GU, Adler CH, Berg D, Klein C, Outeiro TF, Poewe W, Postuma R, and Stoessl AJ
- Subjects
- Humans, Biomedical Research methods, Biomedical Research standards, Synucleinopathies
- Published
- 2024
- Full Text
- View/download PDF
3. IGLON5 Frequency in Idiopathic REM Sleep Behavior Disorder: A Multicenter Study.
- Author
-
Postuma R, Vorasoot N, St Louis EK, Pelletier A, Lim MM, Elliott J, Gagnon JF, Gan-Or Z, Forsberg LK, Fields JA, Ross OA, Singer W, Huddleston DE, Bliwise DL, Avidan AY, Howell M, Schenck CH, McLeland J, Davis AA, Criswell SR, Videnovic A, During EH, Miglis MG, Boeve BF, Ju YS, and McKeon A
- Subjects
- Humans, Male, Female, Aged, Middle Aged, Cohort Studies, REM Sleep Behavior Disorder immunology, REM Sleep Behavior Disorder diagnosis, Autoantibodies blood, Cell Adhesion Molecules, Neuronal immunology
- Abstract
Background and Objectives: Idiopathic/isolated REM sleep behavior disorder (iRBD) has been strongly linked to neurodegenerative synucleinopathies such as Parkinson disease, dementia with Lewy bodies, and multiple system atrophy. However, there have been increasing reports of RBD as a presenting feature of serious and treatable autoimmune syndromes, particularly IGLON5. This study's objective was to investigate the frequency of autoantibodies in a large cohort of participants with iRBD., Methods: Participants were enrolled in the North American Prodromal Synucleinopathy cohort with polysomnography-confirmed iRBD, free of parkinsonism and dementia. Plasma samples were systematically screened for the autoantibodies IGLON5, DPPX, LGI1, and CASPR2 using plasma IgG cell-based assay. Positive or equivocal results were confirmed by repeat testing, plus tissue-based indirect immunofluorescence assay for IGLON5., Results: Of 339 samples analyzed, 3 participants (0.9%) had confirmed positive IGLON5 autoantibodies in the cell-based assay, which were confirmed by the tissue-based assay. An additional participant was positive for CASPR2 with low titer by cell-based assay only (of lower clinical certainty). These cases exhibited a variety of symptoms including dream enactment, cognitive decline, autonomic dysfunction, and motor symptoms. In 1 IGLON5 case and the CASPR2 case, evolution was suggestive of typical synucleinopathy, suggesting the possibility that findings were incidental. However, 2 participants with IGLON5 died before diagnosis was clinically suspected, with a final clinical picture highly suggestive of autoimmune disease., Discussion: Our finding that nearly 1% of a large iRBD cohort may have a serious but potentially treatable autoantibody syndrome has important clinical implications. In particular, it raises the question of whether autoantibody testing for IGLON-5-IgG should be widely implemented for participants with iRBD, considering the difficulty in diagnosis of autoimmune diseases, their response to treatment, and the potential for rapid disease progression. However, any routine testing protocol will also have to consider costs and potential adverse effects of false-positive findings., Trial Registration Information: NCT03623672.
- Published
- 2024
- Full Text
- View/download PDF
4. The Miami Framework for ALS and related neurodegenerative disorders: an integrated view of phenotype and biology.
- Author
-
Benatar M, Wuu J, Huey ED, McMillan CT, Petersen RC, Postuma R, McHutchison C, Dratch L, Arias JJ, Crawley A, Houlden H, McDermott MP, Cai X, Thakur N, Boxer A, Rosen H, Boeve BF, Dacks P, Cosentino S, Abrahams S, Shneider N, Lingor P, Shefner J, Andersen PM, Al-Chalabi A, and Turner MR
- Subjects
- Humans, Neurodegenerative Diseases diagnosis, Neurodegenerative Diseases metabolism, Neurodegenerative Diseases genetics, Biomarkers metabolism, Amyotrophic Lateral Sclerosis genetics, Amyotrophic Lateral Sclerosis diagnosis, Amyotrophic Lateral Sclerosis metabolism, Amyotrophic Lateral Sclerosis pathology, Phenotype, Frontotemporal Dementia genetics, Frontotemporal Dementia diagnosis, Frontotemporal Dementia metabolism
- Abstract
Increasing appreciation of the phenotypic and biological overlap between amyotrophic lateral sclerosis (ALS) and frontotemporal dementia, alongside evolving biomarker evidence for a pre-symptomatic stage of disease and observations that this stage of disease might not always be clinically silent, is challenging traditional views of these disorders. These advances have highlighted the need to adapt ingrained notions of these clinical syndromes to include both the full phenotypic continuum - from clinically silent, to prodromal, to clinically manifest - and the expanded phenotypic spectrum that includes ALS, frontotemporal dementia and some movement disorders. The updated clinical paradigms should also align with our understanding of the biology of these disorders, reflected in measurable biomarkers. The Miami Framework, emerging from discussions at the Second International Pre-Symptomatic ALS Workshop in Miami (February 2023; a full list of attendees and their affiliations appears in the Supplementary Information) proposes a classification system built on: first, three parallel phenotypic axes - motor neuron, frontotemporal and extrapyramidal - rather than the unitary approach of combining all phenotypic elements into a single clinical entity; and second, biomarkers that reflect different aspects of the underlying pathology and biology of neurodegeneration. This framework decouples clinical syndromes from biomarker evidence of disease and builds on experiences from other neurodegenerative diseases to offer a unified approach to specifying the pleiotropic clinical manifestations of disease and describing the trajectory of emergent biomarkers., (© 2024. Springer Nature Limited.)
- Published
- 2024
- Full Text
- View/download PDF
5. Publisher Correction: The Miami Framework for ALS and related neurodegenerative disorders: an integrated view of phenotype and biology.
- Author
-
Benatar M, Wuu J, Huey ED, McMillan CT, Petersen RC, Postuma R, McHutchison C, Dratch L, Arias JJ, Crawley A, Houlden H, McDermott MP, Cai X, Thakur N, Boxer A, Rosen H, Boeve BF, Dacks P, Cosentino S, Abrahams S, Shneider N, Lingor P, Shefner J, Andersen PM, Al-Chalabi A, and Turner MR
- Published
- 2024
- Full Text
- View/download PDF
6. Longitudinal Network Changes and Phenoconversion Risk in Isolated REM Sleep Behavior Disorder.
- Author
-
Eidelberg D, Tang C, Nakano Y, Vo A, Nguyen N, Schindlbeck K, Poston K, Gagnon JF, Postuma R, Niethammer M, Ma Y, Peng S, and Dhawan V
- Abstract
Isolated rapid eye movement sleep behavior disorder (iRBD) is a prodromal syndrome for Parkinson's disease (PD) and related α -synucleinopathies. We conducted a longitudinal imaging study of network changes in iRBD and their relationship to phenoconversion. Expression levels for the PD-related motor and cognitive networks (PDRP and PDCP) were measured at baseline, 2 and 4 years, along with dopamine transporter (DAT) binding. PDRP and PDCP expression increased over time, with higher values in the former network. While abnormal functional connections were identified initially within the PDRP, others bridging the two networks appeared later. A model based on the rates of PDRP progression and putamen dopamine loss predicted phenoconversion within 1.2 years in individuals with iRBD. In aggregate, the data suggest that maladaptive reorganization of brain networks takes place in iRBD years before phenoconversion. Network expression and DAT binding measures can be used together to assess phenoconversion risk in these individuals., Competing Interests: Additional Declarations: There is NO Competing Interest.
- Published
- 2024
- Full Text
- View/download PDF
7. Comparison of Sleep Apnea Questionnaires and Reported Diagnosis in Neurological Disorders of Aging.
- Author
-
Gomes T, Benedetti A, Postuma R, Rizzo D, Baltzan M, Kimoff RJ, and Kaminska M
- Abstract
Background: Obstructive sleep apnea (OSA) is associated with worse outcomes in stroke, Alzheimer's disease (AD) and Parkinson's disease (PD), but diagnosis is challenging in these groups. We aimed to compare the prevalence of high risk of OSA based on commonly used questionnaires and self-reported OSA diagnosis: 1. within groups with stroke, AD, PD and the general population (GP); 2. Between neurological groups and GP., Methods: Individuals with stroke, PD and AD were identified in the Canadian Longitudinal Study of Aging (CLSA) by survey. STOP, STOP-BAG, STOP-B28 and GOAL screening tools and OSA self-report were compared by the Chi-squared test. Logistic regression was used to compare high risk/self-report of OSA, in neurological conditions vs. GP, adjusted for confounders., Results: We studied 30,097 participants with mean age of 62.3 years (SD 10.3) (stroke n = 1791; PD n = 175; AD n = 125). In all groups, a positive GOAL was the most prevalent, while positive STOP was least prevalent among questionnaires. Significant variations in high-risk OSA were observed between different questionnaires across all groups. Under 1.5% of individuals self-reported OSA. While all questionnaires suggested a higher prevalence of OSA in stroke than the GP, for PD and AD, there was heterogeneity depending on questionnaire., Conclusions: The wide range of prevalences of high risk of OSA resulting from commonly used screening tools underscores the importance of validating them in older adults with neurological disorders. OSA was self-reported in disproportionately small numbers across groups, suggesting that OSA is underdiagnosed in older adults or underreported by patients, which is concerning given its increasingly recognized impact on brain health.
- Published
- 2024
- Full Text
- View/download PDF
8. EEG rhythmic and arrhythmic spectral components and functional connectivity at resting state may predict the development of synucleinopathies in idiopathic REM sleep behavior disorder.
- Author
-
Hernandez J, Lina JM, Dubé J, Lafrenière A, Gagnon JF, Montplaisir JY, Postuma RB, and Carrier J
- Abstract
Study Objectives: Idiopathic/isolated REM-sleep behavior disorder (iRBD) often precedes the onset of synucleinopathies. Here, we investigated whether baseline resting-state EEG advanced spectral power and functional connectivity differ between iRBD patients who converted towards a synucleinopathy at follow-up and those who did not., Methods: Eighty-one participants with iRBD (66.89±6.91 years) underwent a baseline resting-state EEG recording, a neuropsychological assessment and a neurological examination. We estimated EEG power spectral density using standard analyses and derived spectral estimates of rhythmic and arrhythmic components. Global and pairwise EEG functional connectivity analyses were computed using the weighted phase-lag index (wPLI). Pixel-based permutation tests were used to compare groups., Results: After a mean follow-up of 5.01±2.76 years, 34 patients were diagnosed with a synucleinopathy (67.81±7.34 years) and 47 remained disease-free (65.53±7.09 years). Among patients who converted, 22 were diagnosed with Parkinson's disease and 12 with dementia with Lewy bodies. As compared to patients who did not convert, patients who converted exhibited at baseline higher relative theta standard power, steeper slopes of the arrhythmic component and higher theta rhythmic power mostly in occipital regions. Furthermore, patients who converted showed higher beta global wPLI but lower alpha wPLI between left temporal and occipital regions., Conclusion: Analyses of resting-state EEG rhythmic and arrhythmic components and functional connectivity suggest an imbalanced excitatory-to-inhibitory activity within large-scale networks, which is associated with later development of a synucleinopathy in iRBD patients., (© The Author(s) 2024. Published by Oxford University Press on behalf of Sleep Research Society.)
- Published
- 2024
- Full Text
- View/download PDF
9. Validation of the RBD Symptom Severity Scale in the North American Prodromal Synucleinopathy Consortium.
- Author
-
Choudhury P, Lee-Iannotti JK, Busicescu AO, Rangan P, Fantini ML, Avidan AY, Bliwise DL, Criswell SR, During EH, Elliott JE, Fields JA, Gagnon JF, Howell MJ, Huddleston DE, McLeland J, Mignot E, Miglis MG, Lim MM, Pelletier A, Schenck CH, Shprecher D, St Louis EK, Videnovic A, Ju YS, Boeve BF, and Postuma R
- Subjects
- Humans, Female, Movement, North America, REM Sleep Behavior Disorder diagnosis, Synucleinopathies, Parasomnias
- Abstract
Background and Objectives: REM sleep behavior disorder (RBD) is a parasomnia characterized by dream enactment. The International RBD Study Group developed the RBD Symptom Severity Scale (RBDSSS) to assess symptom severity for clinical or research use. We assessed the psychometric and clinimetric properties of the RBDSSS in participants enrolled in the North American Prodromal Synucleinopathy (NAPS) Consortium for RBD., Methods: NAPS participants, who have polysomnogram-confirmed RBD, and their bedpartners completed the RBDSSS (participant and bedpartner versions). The RBDSSS contains 8 questions to assess the frequency and severity/impact of (1) dream content, (2) vocalizations, (3) movements, and (4) injuries associated with RBD. Total scores for participant (maximum score = 54) and bedpartner (maximum score = 38) questionnaires were derived by multiplying frequency and severity scores for each question. The Clinical Global Impression Scale of Severity (CGI-S) and RBD symptom frequency were assessed by a physician during a semistructured clinical interview with participants and, if available, bedpartners. Descriptive analyses, correlations between overall scores, and subitems were assessed, and item response analysis was performed to determine the scale's validity., Results: Among 261 study participants, the median (interquartile range) score for the RBDSSS-PT (participant) was 10 (4-18) and that for the RBDSSS-BP (bedpartner) was 8 (4-15). The median CGI-S was 3 (3-4), indicating moderate severity. RBDSSS-BP scores were significantly lower in women with RBD (6 vs 9, p = 0.02), while there were no sex differences in RBDSSS-PT scores (8 vs 10.5, p = 0.615). Positive correlations were found between RBDSSS-PT vs RBDSSS-BP (Spearman r
s = 0.561), RBDSSS-PT vs CGI-S ( rs = 0.556), and RBDSSS-BP vs CGI-S ( rs = 0.491, all p < 0.0001). Item response analysis showed a high discriminatory value (range 1.40-2.12) for the RBDSSS-PT and RBDSSS-BP (1.29-3.47)., Discussion: We describe the RBDSSS with adequate psychometric and clinimetric properties to quantify RBD symptom severity and good concordance between participant and bedpartner questionnaires and between RBDSSS scores and clinician-assessed global severity.- Published
- 2024
- Full Text
- View/download PDF
10. 99m Tc-HMPAO SPECT Perfusion Signatures Associated With Clinical Progression in Patients With Isolated REM Sleep Behavior Disorder.
- Author
-
Rahayel S, Postuma R, Baril AA, Misic B, Pelletier A, Soucy JP, Montplaisir J, Dagher A, and Gagnon JF
- Subjects
- Male, Humans, Female, Tomography, Emission-Computed, Single-Photon, Perfusion, Disease Progression, Parkinson Disease complications, Parkinson Disease diagnostic imaging, REM Sleep Behavior Disorder complications, Lewy Body Disease, Synucleinopathies complications
- Abstract
Background and Objectives: Idiopathic/isolated REM sleep behavior disorder (iRBD) is associated with dementia with Lewy bodies and Parkinson disease. Despite evidence of abnormal cerebral perfusion in iRBD, there is currently no pattern that can predict whether an individual will develop dementia with Lewy bodies or Parkinson disease. The objective was to identify a perfusion signature associated with conversion to dementia with Lewy bodies in iRBD., Methods: Patients with iRBD underwent video-polysomnography, neurologic and neuropsychological assessments, and baseline
99m Tc-HMPAO SPECT to assess relative cerebral blood flow. Partial least squares correlation was used to identify latent variables that maximized covariance between 27 clinical features and relative gray matter perfusion. Patient-specific scores on the latent variables were used to test the association with conversion to dementia with Lewy bodies compared with that with Parkinson disease. The signature's expression was also assessed in 24 patients with iRBD who underwent a second perfusion scan, 22 healthy controls, and 19 individuals with Parkinson disease., Results: Of the 137 participants, 93 underwent SPECT processing, namely 52 patients with iRBD (67.9 years, 73% men), 19 patients with Parkinson disease (67.3 years, 37% men), and 22 controls (67.0 years, 73% men). Of the 47 patients with iRBD followed up longitudinally (4.5 years), 12 (26%) developed a manifest synucleinopathy (4 dementia with Lewy bodies and 8 Parkinson disease). Analysis revealed 2 latent variables between relative blood flow and clinical features: the first was associated with a broad set of features that included motor, cognitive, and perceptual variables, age, and sex; the second was mostly associated with cognitive features and RBD duration. When brought back into the patient's space, the expression of the first variable was associated with conversion to a manifest synucleinopathy, whereas the second was associated with conversion to dementia with Lewy bodies. The expression of the patterns changed over time and was associated with worse motor features., Discussion: This study identified a brain perfusion signature associated with cognitive impairment in iRBD and transition to dementia with Lewy bodies. This signature, which can be derived from individual scans, has the potential to be developed into a biomarker that predicts dementia with Lewy bodies in at-risk individuals.- Published
- 2024
- Full Text
- View/download PDF
11. A biological classification of Parkinson's disease: the SynNeurGe research diagnostic criteria.
- Author
-
Höglinger GU, Adler CH, Berg D, Klein C, Outeiro TF, Poewe W, Postuma R, Stoessl AJ, and Lang AE
- Subjects
- Humans, Neuroimaging, Precision Medicine, Parkinson Disease diagnosis, Parkinson Disease genetics
- Abstract
With the hope that disease-modifying treatments could target the molecular basis of Parkinson's disease, even before the onset of symptoms, we propose a biologically based classification. Our classification acknowledges the complexity and heterogeneity of the disease by use of a three-component system (SynNeurGe): presence or absence of pathological α-synuclein (S) in tissues or CSF; evidence of underlying neurodegeneration (N) defined by neuroimaging procedures; and documentation of pathogenic gene variants (G) that cause or strongly predispose to Parkinson's disease. These three components are linked to a clinical component (C), defined either by a single high-specificity clinical feature or by multiple lower-specificity clinical features. The use of a biological classification will enable advances in both basic and clinical research, and move the field closer to the precision medicine required to develop disease-modifying therapies. We emphasise the initial application of these criteria exclusively for research. We acknowledge its ethical implications, its limitations, and the need for prospective validation in future studies., Competing Interests: Declaration of interests GUH reports participation in industry-sponsored research projects from AbbVie, Bial, Biogen, Biohaven, Novartis, Sanofi, Takeda, and UCB; served as a consultant for AbbVie, Alzprotect, Aprineua, Asceneuron, Bial, Biogen, Biohaven, Kyowa Kirin, Lundbeck, Novartis, Retrotope, Roche, Sanofi, and UCB; received honoraria for scientific presentations from AbbVie, Bayer Vital, Bial, Biogen, Bristol Myers Squibb, Kyowa Kirin, Roche, Teva, UCB, and Zambon; received publication royalties from Academic Press, Kohlhammer, and Thieme; and holds a patent on the Treatment of Synucleinopathies (US patent: US 10,918,628 B2; European patent: EP 17 787 904·6–1109/3 525 788). CHA reports consultant fees from Cionic, CND Life Science, Jazz, Neurocrine, Precon Health, and XW Pharma. DB reports having served on advisory boards of UCB Pharma and ACImmune; received honoraria from Biogen, UCB Pharma, and Novartis; and her research was supported by UCB Pharma, the European Union, Novartis Pharma, and Lundbeck. CK is deputy editor of Movement Disorders and associate editor of Annals of Neurology; serves as a medical adviser to Centogene for genetic testing reports in the fields of movement disorders and dementia, excluding Parkinson's disease; serves as a medical advisor to Retromer Therapeutics; received honoraria for scientific presentations from Bial and Desitin; and does not hold any stocks or stock options with any companies that are connected to Parkinson's disease or to any of the topics in this Personal View; WP reports personal fees from AbbVie, AFFiRiS, AstraZeneca, Bial, Boston Scientific, Britannia, Intec, Ipsen, Lundbeck, NeuroDerm, Neurocrine, Denali Pharmaceuticals, Novartis, Orion Pharma, Prexton, Teva, UCB, and Zambon; royalties from Thieme, Wiley Blackwell, Oxford University Press, and Cambridge University Press. RP received personal fees as an advisor from Takeda, Roche, Biogen, AbbVie, Curasen, Lilly, Novartis, Eisai, Merck, and Vaxxinity; and received a stipend from the International Parkinson and Movement Disorder Society. AJS chairs a data safety monitoring board for Neurocrine; serves on a data safety monitoring board for AskBio; serves as an advisor to Capsidia; receives a stipend from the International Parkinson & Movement Disorder Society as editor-in-chief of Movement Disorders. AEL has served as an advisor for AbbVie, AFFiRis, Alector, Amylyx, Aprinoia, Biogen, BioAdvance, BlueRock, Biovie, Bristol MyersSquibb, CoA Therapeutics, Denali, Janssen, Jazz, Lilly, Novartis, Paladin, Pharma 2B, PsychoGenetics, Retrophin, Roche, Sun Pharma, and UCB; received honoraria from Sun Pharma, AbbVie and Sunovion; is serving as an expert witness in litigation related to paraquat and Parkinson's disease; received publishing royalties from Elsevier, Saunders, Wiley-Blackwell, Johns Hopkins Press, and Cambridge University Press; and co-shares a patent for diagnostic assays for movement disorders that includes alpha-synuclein seeding assay testing. TFO reports no competing interests., (Copyright © 2024 Elsevier Ltd. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
12. Frequency of Orthostatic Hypotension in Isolated REM Sleep Behavior Disorder.
- Author
-
Elliott JE, Bryant-Ekstrand MD, Keil AT, Ligman BR, Lim MM, Zitser J, During EH, Gagnon JF, St Louis EK, Fields JA, Huddleston DE, Bliwise DL, Avidan AY, Schenck CH, McLeland J, Criswell SR, Davis AA, Videnovic A, Lee-Iannotti JK, Postuma R, Boeve BF, Ju YS, and Miglis MG
- Subjects
- Humans, Male, Female, REM Sleep Behavior Disorder diagnosis, Hypotension, Orthostatic diagnosis, Hypotension, Orthostatic epidemiology, Synucleinopathies, Parkinson Disease complications, Parkinson Disease epidemiology, Autonomic Nervous System Diseases diagnosis, Autonomic Nervous System Diseases epidemiology
- Abstract
Background and Objectives: Although orthostatic hypotension (OH) can be an early feature of autonomic dysfunction in isolated REM sleep behavior disorder (iRBD), no large-scale studies have examined the frequency of OH in iRBD. In this study, we prospectively evaluated the frequency of OH in a large multicenter iRBD cohort., Methods: Participants 18 years or older with video polysomnogram-confirmed iRBD were enrolled through the North American Prodromal Synucleinopathy consortium. All participants underwent 3-minute orthostatic stand testing to assess the frequency of OH, and a Δ heart rate/Δ systolic blood pressure (ΔHR/ΔSBP) ratio <0.5 was used to define reduced HR augmentation, suggestive of neurogenic OH. All participants completed a battery of assessments, including the Scales for Outcomes in Parkinson Disease-Autonomic Dysfunction (SCOPA-AUT) and others assessing cognitive, motor, psychiatric, and sensory domains., Results: Of 340 iRBD participants (65 ± 10 years, 82% male), 93 (27%) met criteria for OH (ΔHR/ΔSBP 0.37 ± 0.28; range 0.0-1.57), and of these, 72 (77%) met criteria for OH with reduced HR augmentation (ΔHR/ΔSBP 0.28 ± 0.21; range 0.0-0.5). Supine hypertension (sHTN) was present in 72% of those with OH. Compared with iRBD participants without OH, those with OH were older, reported older age of RBD symptom onset, and had worse olfaction. There was no difference in autonomic symptom scores as measured by SCOPA-AUT., Discussion: OH and sHTN are common in iRBD. However, as patients may have reduced autonomic symptom awareness, orthostatic stand testing should be considered in clinical evaluations. Longitudinal studies are needed to clarify the relationship between OH and phenoconversion risk in iRBD., Trial Registration Information: ClinicalTrials.gov: NCT03623672; North American Prodromal Synucleinopathy Consortium.
- Published
- 2023
- Full Text
- View/download PDF
13. Parkinson's Disease Subtypes: Critical Appraisal and Recommendations.
- Author
-
Mestre TA, Fereshtehnejad SM, Berg D, Bohnen NI, Dujardin K, Erro R, Espay AJ, Halliday G, van Hilten JJ, Hu MT, Jeon B, Klein C, Leentjens AFG, Marinus J, Mollenhauer B, Postuma R, Rajalingam R, Rodríguez-Violante M, Simuni T, Surmeier DJ, Weintraub D, McDermott MP, Lawton M, and Marras C
- Subjects
- Humans, Precision Medicine, Prognosis, Parkinson Disease diagnosis, Parkinson Disease therapy
- Abstract
Background: In Parkinson's disease (PD), there is heterogeneity in the clinical presentation and underlying biology. Research on PD subtypes aims to understand this heterogeneity with potential contribution for the knowledge of disease pathophysiology, natural history and therapeutic development. There have been many studies of PD subtypes but their impact remains unclear with limited application in research or clinical practice., Objective: To critically evaluate PD subtyping systems., Methods: We conducted a systematic review of PD subtypes, assessing the characteristics of the studies reporting a subtyping system for the first time. We completed a critical appraisal of their methodologic quality and clinical applicability using standardized checklists., Results: We included 38 studies. The majority were cross-sectional (n = 26, 68.4%), used a data-driven approach (n = 25, 65.8%), and non-clinical biomarkers were rarely used (n = 5, 13.1%). Motor characteristics were the domain most commonly reported to differentiate PD subtypes. Most of the studies did not achieve the top rating across items of a Methodologic Quality checklist. In a Clinical Applicability Checklist, the clinical importance of differences between subtypes, potential treatment implications and applicability to the general population were rated poorly, and subtype stability over time and prognostic value were largely unknown., Conclusion: Subtyping studies undertaken to date have significant methodologic shortcomings and most have questionable clinical applicability and unknown biological relevance. The clinical and biological signature of PD may be unique to the individual, rendering PD resistant to meaningful cluster solutions. New approaches that acknowledge the individual-level heterogeneity and that are more aligned with personalized medicine are needed.
- Published
- 2021
- Full Text
- View/download PDF
14. Dream enactment behavior: review for the clinician.
- Author
-
Baltzan M, Yao C, Rizzo D, and Postuma R
- Subjects
- Child, Humans, Sleep, REM, REM Sleep Behavior Disorder diagnosis, Sleep Wake Disorders
- Abstract
None: Dream enactment behavior commonly occurs on occasion in normal children and adults. Disruptive and frequent dream enactment behavior may come to the attention of the clinician either as the primary reason for consultation or as a prominent characteristic of a patient with other sleep disorders. Questioning patients with chronic neurologic and psychiatric disorders may also reveal previously unrecognized behavior. In the absence of sleep pathology, process of dream enactment likely begins with active, often emotionally charged dream content that may occasionally break through the normal REM sleep motor suppressive activity. Disrupted sleep resulting from many possible causes, such as circadian disruption, sleep apnea, or medications, may also disrupt at least temporarily the motor-suppressive activity in REM sleep, allowing dream enactment to occur. Finally, pathological neurological damage in the context of degenerative, autoimmune, and infectious neurological disorders may lead to chronic recurrent and severe dream enactment behavior. Evaluating the context, frequency, and severity of dream enactment behavior is guided first and foremost by a structured approach to the sleep history. Physical exam and selected testing support the clinical diagnosis. Understanding the context and the likely cause is essential to effective therapy., (© 2020 American Academy of Sleep Medicine.)
- Published
- 2020
- Full Text
- View/download PDF
15. Deep Learning With EEG Spectrograms in Rapid Eye Movement Behavior Disorder.
- Author
-
Ruffini G, Ibañez D, Castellano M, Dubreuil-Vall L, Soria-Frisch A, Postuma R, Gagnon JF, and Montplaisir J
- Abstract
REM Behavior Disorder (RBD) is now recognized as the prodromal stage of α-synucleinopathies such as Parkinson's disease (PD). In this paper, we describe deep learning models for diagnosis/prognosis derived from a few minutes of eyes-closed resting electroencephalography data (EEG) collected at baseline from idiopathic RBD patients ( n = 121) and healthy controls (HC, n = 91). A few years after the EEG acquisition (4±2 years), a subset of the RBD patients were eventually diagnosed with either PD ( n = 14) or Dementia with Lewy bodies (DLB, n = 13), while the rest remained idiopathic RBD. We describe first a simple deep convolutional neural network (DCNN) with a five-layer architecture combining filtering and pooling, which we train using stacked multi-channel EEG spectrograms from idiopathic patients and healthy controls. We treat the data as in audio or image classification problems where deep networks have proven successful by exploiting invariances and compositional features in the data. For comparison, we study a simple deep recurrent neural network (RNN) model using three stacked Long Short Term Memory network (LSTM) cells or gated-recurrent unit (GRU) cells-with very similar results. The performance of these networks typically reaches 80% (±1%) classification accuracy in the balanced HC vs. PD-conversion classification problem. In particular, using data from the best single EEG channel, we obtain an area under the curve (AUC) of 87% (±1%)-while avoiding spectral feature selection. The trained classifier can also be used to generate synthetic spectrograms using the DeepDream algorithm to study what time-frequency features are relevant for classification. We find these to be bursts in the theta band together with a decrease of bursting in the alpha band in future RBD converters (i.e., converting to PD or DLB in the follow up) relative to HCs. From this first study, we conclude that deep networks may provide a useful tool for the analysis of EEG dynamics even from relatively small datasets, offering physiological insights and enabling the identification of clinically relevant biomarkers.
- Published
- 2019
- Full Text
- View/download PDF
16. High burden of neurological disease in the older general population: results from the Canadian Longitudinal Study on Aging.
- Author
-
Wolfson C, Fereshtehnejad SM, Pasquet R, Postuma R, and Keezer MR
- Subjects
- Aged, Aged, 80 and over, Canada epidemiology, Chronic Disease, Comorbidity, Emergency Service, Hospital, Female, Humans, Longitudinal Studies, Male, Middle Aged, Prevalence, Epilepsy epidemiology, Migraine Disorders epidemiology, Multiple Sclerosis epidemiology, Parkinsonian Disorders epidemiology, Stroke epidemiology
- Abstract
Background and Purpose: Our objective was to study the association between the presence of a neurological disease and the comorbidity burden as well as healthcare utilization (HCU)., Methods: Using baseline data from the Canadian Longitudinal Study on Aging (CLSA), we examined the burden of five neurological conditions. The CLSA is a population-based study of approximately 50 000 individuals, aged 45-85 years at baseline. We used multivariable Poisson regression to identify correlates of comorbidity burden and HCU., Results: The lifetime prevalence of five neurological diseases is presented: epilepsy, Parkinson's disease/parkinsonism, stroke/transient ischaemic attack, multiple sclerosis and migraine. We found the somatic and psychiatric comorbidity burden to be higher in those individuals with a neurological disease (an 18-45% mean increase in the number of chronic conditions) as compared with the comparison group without a neurological disease, except for Parkinson's disease/parkinsonism. The presence of a neurological disease was associated with only a modest increase in the probability of visiting a general practitioner but was associated with a greatly increased probability of visiting a medical specialist (up to 68% more likely) or an emergency department (up to 79% more likely) and an overnight hospitalization (up to 108% more likely)., Conclusions: We found striking associations between our neurological diseases and increased comorbidity burdens and HCU. These findings are important for informing public policy planning as well as driving avenues for future research. The present study established the CLSA as an important research platform for the study of neurological conditions in an aging general population., (© 2018 EAN.)
- Published
- 2019
- Full Text
- View/download PDF
17. Basic clinical features do not predict dopamine transporter binding in idiopathic REM behavior disorder.
- Author
-
Chahine LM, Iranzo A, Fernández-Arcos A, Simuni T, Seedorff N, Caspell-Garcia C, Amara AW, Comella C, Högl B, Hamilton J, Marek K, Mayer G, Mollenhauer B, Postuma R, Tolosa E, Trenkwalder C, Videnovic A, and Oertel W
- Abstract
REM sleep behavior disorder (RBD) is strongly associated with development of Parkinson's Disease and other α-synuclein-related disorders. Dopamine transporter (DAT) binding deficit predicts conversion to α-synuclein-related disorders in individuals with RBD. In turn, identifying which individuals with RBD have the highest likelihood of having abnormal DAT binding would be useful. The objective of this analysis was to examine if there are basic clinical predictors of DAT deficit in RBD. Participants referred for inclusion in the RBD cohort of the Parkinson Progression Markers Initiative were included. Assessments at the screening visit including DAT SPECT imaging, physical examination, cognitive function screen, and questionnaire-based non-motor assessment. The group with DAT binding deficit ( n = 49) was compared to those without ( n = 26). There were no significant differences in demographic or clinical features between the two groups. When recruiting RBD cohorts enriched for high risk of neurodegenerative disorders, our data support the need for objective biomarker assessments., Competing Interests: The authors declare no competing interests.
- Published
- 2019
- Full Text
- View/download PDF
18. The GBA p.Trp378Gly mutation is a probable French-Canadian founder mutation causing Gaucher disease and synucleinopathies.
- Author
-
Ruskey JA, Zhou S, Santiago R, Franche LA, Alam A, Roncière L, Spiegelman D, Fon EA, Trempe JF, Kalia LV, Postuma RB, Dupre N, Rivard GE, Assouline S, Amato D, and Gan-Or Z
- Subjects
- Adolescent, Adult, Aged, Child, Preschool, Female, Haplotypes, Heterozygote, Humans, Infant, Male, Middle Aged, Polymorphism, Single Nucleotide, Principal Component Analysis, Quebec, Young Adult, Founder Effect, Gaucher Disease genetics, Glucosylceramidase genetics, Glycine genetics, Mutation, Synucleins genetics, Tryptophan genetics
- Abstract
Biallelic GBA mutations cause Gaucher disease (GD), and heterozygous carriers are at risk for synucleinopathies. No founder GBA mutations in French-Canadians are known. GBA was fully sequenced using targeted next generation and Sanger sequencing in French-Canadian Parkinson disease (PD) patients (n = 436), rapid eye movement (REM)-sleep behavior disorder (RBD) patients (n = 189) and controls (n = 891). Haplotype, identity-by-descent (IBD) and principal component analyses (PCA) were performed using single nucleotide polymorphism-chip data. Data on GD patients from Toronto and Montreal were collected from patients' files. A GBA p.Trp378Gly mutation was identified in two RBD and four PD patients (1% of all patients combined), and not in controls. The two RBD patients had converted to DLB within 3 years of their diagnosis. Haplotype, IBD and PCA analysis demonstrated that this mutation is from a single founder. Out of 167 GD patients screened, 15 (9.0%) carried the p.Trp378Gly mutation, all in trans with p.Asn370Ser. Three (20%) of the GD patients with the p.Trp378Gly mutation had developed Parkinsonism, and 11 patients had family history of PD. The p.Trp378Gly mutation is the first French-Canadian founder GBA mutation to be described, which leads to synucleinopathies and to GD type 1 when in compound heterozygosity with p.Asn370Ser., (© 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)
- Published
- 2018
- Full Text
- View/download PDF
19. Answer to a Commentary on "Tango for treatment of motor and non-motor manifestations in Parkinson's disease: A randomized control study".
- Author
-
Rios Romenets S, Fereshtehnejad SM, and Postuma R
- Subjects
- Gait, Humans, Dance Therapy, Parkinson Disease
- Published
- 2018
- Full Text
- View/download PDF
20. Prevalence and determinants of rapid eye movement sleep behavior disorder in the general population.
- Author
-
Haba-Rubio J, Frauscher B, Marques-Vidal P, Toriel J, Tobback N, Andries D, Preisig M, Vollenweider P, Postuma R, and Heinzer R
- Abstract
Study Objectives: Rapid eye movement (REM) sleep behavior disorder (RBD) is a parasomnia associated with neurodegenerative synucleinopathies. Its prevalence is largely unknown. This study determined the prevalence and characteristics of RBD in the general population using gold-standard polysomnography., Methods: Full polysomnographic data from 1,997 participants (age = 59 ± 11.1 years, 53.6% women) participating in a population-based study (HypnoLaus, Lausanne, Switzerland) were collected. Sleep-related complaints and habits were investigated using various sleep measures including the Munich Parasomnia Screening (MUPS) questionnaire, which includes two questions evaluating complex motor behaviors suggestive of RBD. Full polysomnography was performed at home. For participants screening positive for RBD, muscle activity during REM sleep was quantified to diagnose RBD., Results: Three hundred sixty-eight participants endorsed dream-enactment behavior on either of the two MUPS questions, and 21 fulfilled polysomnographic criteria for RBD, resulting in an estimated prevalence of 1.06% (95% CI = 0.61-1.50), with no difference between men and women. Compared with RBD- participants, RBD+ took more frequently antidepressants and antipsychotics (23.8% vs. 5.4%, p = .005; 14.3% vs. 1.5%, p = .004, respectively) and were more frequently smokers or ex-smokers (85% vs. 56.6%, p = .011). On polysomnography, RBD+ had more stage N2 sleep (52 ± 11.5% vs. 46.3 ± 10.2%, p = .024) and less REM sleep (18 ± 6.4% vs. 21.9 ± 6.2%, p = .007), lower apnea-hypopnea index in REM sleep (3.8 ± 5.2 vs. 8.9 ± 13/hour, p = .035), and lower autonomic arousal index (31 ± 14.9 vs. 42.6 ± 19.5/hour, p = .002)., Conclusions: In our middle-to-older age population-based sample, the prevalence of RBD was 1.06%, with no difference between men and women. RBD was associated with antidepressant and antipsychotic use and with minor differences in sleep structure., (© Sleep Research Society 2017. Published by Oxford University Press on behalf of the Sleep Research Society. All rights reserved. For permissions, please e-mail journals.permissions@oup.com.)
- Published
- 2018
- Full Text
- View/download PDF
21. Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy.
- Author
-
Obeso JA, Stamelou M, Goetz CG, Poewe W, Lang AE, Weintraub D, Burn D, Halliday GM, Bezard E, Przedborski S, Lehericy S, Brooks DJ, Rothwell JC, Hallett M, DeLong MR, Marras C, Tanner CM, Ross GW, Langston JW, Klein C, Bonifati V, Jankovic J, Lozano AM, Deuschl G, Bergman H, Tolosa E, Rodriguez-Violante M, Fahn S, Postuma RB, Berg D, Marek K, Standaert DG, Surmeier DJ, Olanow CW, Kordower JH, Calabresi P, Schapira AHV, and Stoessl AJ
- Subjects
- Anniversaries and Special Events, History, 19th Century, History, 20th Century, History, 21st Century, Humans, Parkinson Disease history
- Abstract
This article reviews and summarizes 200 years of Parkinson's disease. It comprises a relevant history of Dr. James Parkinson's himself and what he described accurately and what he missed from today's perspective. Parkinson's disease today is understood as a multietiological condition with uncertain etiopathogenesis. Many advances have occurred regarding pathophysiology and symptomatic treatments, but critically important issues are still pending resolution. Among the latter, the need to modify disease progression is undoubtedly a priority. In sum, this multiple-author article, prepared to commemorate the bicentenary of the shaking palsy, provides a historical state-of-the-art account of what has been achieved, the current situation, and how to progress toward resolving Parkinson's disease. © 2017 International Parkinson and Movement Disorder Society., (© 2017 International Parkinson and Movement Disorder Society.)
- Published
- 2017
- Full Text
- View/download PDF
22. Longitudinal assessment of excessive daytime sleepiness in early Parkinson's disease.
- Author
-
Amara AW, Chahine LM, Caspell-Garcia C, Long JD, Coffey C, Högl B, Videnovic A, Iranzo A, Mayer G, Foldvary-Schaefer N, Postuma R, Oertel W, Lasch S, Marek K, and Simuni T
- Subjects
- Adult, Aged, Case-Control Studies, Cross-Sectional Studies, Disorders of Excessive Somnolence chemically induced, Disorders of Excessive Somnolence epidemiology, Dopamine Agents adverse effects, Dopamine Agents therapeutic use, Dose-Response Relationship, Drug, Female, Humans, Longitudinal Studies, Male, Middle Aged, Neurologic Examination drug effects, Parkinson Disease drug therapy, Parkinson Disease epidemiology, Prognosis, Sleep Wake Disorders diagnosis, Sleep Wake Disorders drug therapy, Sleep Wake Disorders epidemiology, Disorders of Excessive Somnolence diagnosis, Parkinson Disease diagnosis
- Abstract
Background: Excessive daytime sleepiness (EDS) is common and disabling in Parkinson's disease (PD). Predictors of EDS are unclear, and data on biological correlates of EDS in PD are limited. We investigated clinical, imaging and biological variables associated with longitudinal changes in sleepiness in early PD., Methods: The Parkinson's Progression Markers Initiative is a prospective cohort study evaluating progression markers in participants with PD who are unmedicated at baseline (n=423) and healthy controls (HC; n=196). EDS was measured with the Epworth Sleepiness Scale (ESS). Clinical, biological and imaging variables were assessed for associations with EDS for up to 3 years. A machine learning approach (random survival forests) was used to investigate baseline predictors of incident EDS., Results: ESS increased in PD from baseline to year 3 (mean±SD 5.8±3.5 to 7.55±4.6, p<0.0001), with no change in HC. Longitudinally, EDS in PD was associated with non-tremor dominant phenotype, autonomic dysfunction, depression, anxiety and probable behaviour disorder, but not cognitive dysfunction or motor severity. Dopaminergic therapy was associated with EDS at years 2 and 3, as dose increased. EDS was also associated with presynaptic dopaminergic dysfunction, whereas biofluid markers at year 1 showed no significant associations with EDS. A predictive index for EDS was generated, which included seven baseline characteristics, including non-motor symptoms and cerebrospinal fluid phosphorylated-tau/total-tau ratio., Conclusions: In early PD, EDS increases significantly over time and is associated with several clinical variables. The influence of dopaminergic therapy on EDS is dose dependent. Further longitudinal analyses will better characterise associations with imaging and biomarkers., Competing Interests: Competing interests: AWA is an investigator for studies sponsored by the Michael J. Fox Foundation for Parkinson’s Research and Abbvie. JDL has a consulting agreement with NeuroPhage and is a paid consultant for Roche Pharma and Azevan Pharmaceuticals. BH received honoraria as a consultant, for advisory board and/or for speaking for UCB, Otsuka, Lundbeck, Lilly, Axovant and Mundipharma, and Travel Support from Habel Medizintechnik and Vivisol, Austria. GM is an investigator for studies sponsored by UCB Pharma Brussels, Novartis, Michael J. Fox Foundation for Parkinson’s Research, Paul Ehrlich Institute Langen/Germany, Jazz Pharma/USA and Bioprojet; serves on speaker’s bureau for UCB Pharma Brussels; and is on the advisory board of UCB Pharma. RP receives speaker fees from Boehringer, Novartis Canada and Teva Neurosciences. SL is employed by Molecular NeuroImaging, LLC. KM has ownership in inviCRO, LLC and a consultant for Pfizer, GE Healthcare, Lilly, BMS, Piramal, Biogen, Prothena, Roche, Neuropore, US WorldMeds, Neurophage, UCB, Oxford Biomedica and Lysosomal Therapetic, Inc. TS has received consulting honoraria from National Parkinson Foundation, Teva Pharmaceuticals, Pfizer, Harbor, UCB, IMPAX, Acadia, Lundbeck, Eli Lilly and Company, Allergan, Merz Inc and US WorldMeds., (© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.)
- Published
- 2017
- Full Text
- View/download PDF
23. Orthoptic Treatment of Convergence Insufficiency in Parkinson's Disease: A Case Series.
- Author
-
Kergoat H, Law C, Chriqui E, Kergoat MJ, Leclerc BS, Panisset M, Postuma R, and Irving EL
- Abstract
Introduction: This study reports a case series of orthoptic treatment (OT) for convergence insufficiency (CI) in individuals with Parkinson's disease (PD). Method: We are reporting two cases of individuals with PD who completed OT for CI. Both had a confirmed diagnosis of CI, accompanied by CI-type symptomatology. They each underwent an OT program consisting of three office-based visits and 8 weeks of home-based exercises. Treatment outcome was based on the changes measured pre- versus post-OT on the near point of convergence, positive fusional vergences, and symptomatology score. Results: The two participants successfully completed therapy, gained ability to converge, had fewer symptoms, and were satisfied with the OT-induced changes they felt in their day-to-day lives. Conclusion: This case series show that OT for CI in PD is possible. Further research is required as these results demonstrate that OT has the potential to improve symptomatic CI in these patients. In the meantime, the positive results obtained in these two cases should encourage clinicians to consider OT (a therapy with no/minimal risk) for CI in patients with PD whose quality of life is affected by this binocular dysfunction., Competing Interests: Declaration of Conflicting Interests: The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
- Published
- 2017
- Full Text
- View/download PDF
24. Prevalence of Convergence Insufficiency in Parkinson's Disease.
- Author
-
Irving EL, Chriqui E, Law C, Kergoat MJ, Leclerc BS, Panisset M, Postuma R, and Kergoat H
- Abstract
Background: We recently reported that convergence insufficiency (CI)-type visual symptomatology was more prevalent in participants with Parkinson's disease (PD), compared to controls. The objective of this work was to determine the prevalence of a confirmed clinical diagnosis of CI in PD, compared to controls., Methods: Participants with (n = 80) and without (n = 80) PD were recruited and received an eye exam. Published criteria were used to arrive at a clinical diagnosis of CI. The Convergence Insufficiency Symptom Survey (CISS-15) questionnaire was administered to each participant, with a score of ≥21 being considered positive for CI symptomatology. Student t test, chi-square, or nonparametric tests at the 0.05 level were used for statistical significance., Results: A total of 43.8% of participants with versus 16.3% without PD had a clinical diagnosis of CI ( P ≤ 0.001). A total of 53.8% of participants with versus 18.8% without PD had scores on the CISS-15 of ≥21 ( P ≤ 0.001)., Conclusions: These results indicate that individuals with PD have a higher prevalence of CI and CI symptomatology than controls. These data provide evidence supporting the notion that treatment for symptomatic CI should be investigated in individuals with PD.
- Published
- 2016
- Full Text
- View/download PDF
25. Longitudinal changes in cognition in early Parkinson's disease patients with REM sleep behavior disorder.
- Author
-
Chahine LM, Xie SX, Simuni T, Tran B, Postuma R, Amara A, Oertel WH, Iranzo A, Scordia C, Fullard M, Linder C, Purri R, Darin A, Rennert L, Videnovic A, Del Riva P, and Weintraub D
- Subjects
- Aged, Cognitive Dysfunction psychology, Cohort Studies, Disease Progression, Female, Follow-Up Studies, Humans, Internationality, Longitudinal Studies, Male, Middle Aged, Parkinson Disease psychology, Prospective Studies, REM Sleep Behavior Disorder psychology, Cognitive Dysfunction diagnosis, Cognitive Dysfunction epidemiology, Parkinson Disease diagnosis, Parkinson Disease epidemiology, REM Sleep Behavior Disorder diagnosis, REM Sleep Behavior Disorder epidemiology
- Abstract
Introduction: Cognitive decline is common in Parkinson's disease (PD), and identifying patients at highest risk for it is essential. We aimed to examine the effect of possible REM sleep behavior disorder (pRBD) on rate of cognitive decline in early PD, for both global cognition and in specific cognitive domains., Methods: Parkinson's Progression Markers Initiative (PPMI) is a multi-site, international study of PD patients untreated at enrollment. pRBD was assessed with the REM sleep behavior disorder questionnaire (RBDSQ). Global cognition was assessed at baseline and annually using the Montreal Cognitive Assessment (MoCA) and a cognitive battery. Linear mixed effects models were used to examine the relationship between pRBD (RBDSQ≥6) and rate of change in cognitive variables. Age, sex, years of education, and baseline motor and cognitive scores were included as covariates., Results: The baseline sample consisted of 423 individuals with PD, mean age 61.7 years and 65.5% male. Data was available on 389, 366, and 196 participants at 1-year, 2-year, and 3-year follow-up respectively. Possible RBD occurred in 108 (25.5%) at baseline. In multivariate analyses, baseline RBD was associated with greater annual rate of decline in MoCA score (β = -0.34, 95%CI -0.54, -0.13, p < 0.001), Symbol Digit Modalities Test (β = -0.69, 95%CI -1.3, -0.09, p = 0.024), and Hopkins Verbal Learning Test-Revised, delayed free recall (β = -0.21, 95%CI -0.41, -0.013, p = 0.037)., Conclusions: Possible RBD is common in early PD and predicts future cognitive decline, particularly in attention and memory domains., Competing Interests: None of the authors have potential conflicts of interest that relate to the research covered in the article., (Copyright © 2016. Published by Elsevier Ltd.)
- Published
- 2016
- Full Text
- View/download PDF
26. Correlates of excessive daytime sleepiness in de novo Parkinson's disease: A case control study.
- Author
-
Simuni T, Caspell-Garcia C, Coffey C, Chahine LM, Lasch S, Oertel WH, Mayer G, Högl B, Postuma R, Videnovic A, Amara AW, and Marek K
- Subjects
- Adult, Aged, Aged, 80 and over, Case-Control Studies, Comorbidity, Disorders of Excessive Somnolence epidemiology, Female, Humans, Male, Middle Aged, Parkinson Disease epidemiology, Disorders of Excessive Somnolence diagnosis, Parkinson Disease diagnosis
- Abstract
Objective: This study was undertaken to determine the frequency and correlates of excessive daytime sleepiness in de novo, untreated Parkinson's disease (PD) patients compared with the matched healthy controls., Methods: Data were obtained from the Parkinson's Progression Markers Initiative, an international study of de novo, untreated PD patients and healthy controls. At baseline, participants were assessed with a wide range of motor and nonmotor scales, including the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS). Excessive daytime sleepiness was assessed based on the Epworth Sleepiness scale (ESS), with a cutoff of 10., Results: Four hundred twenty-three PD subjects and 196 healthy controls were recruited into the study. Mean ESS (min, max) score was 5.8 (0, 20) for the PD subjects and 5.6 (0, 19) for healthy controls (P = 0.54). Sixty-six (15.6%) PD subjects and 24 (12%) healthy controls had ESS of at least 10 (P = 0.28). No difference was seen in demographic characteristics, age of onset, disease duration, PD subtype, cognitive status, or utilization of sedatives between the PD sleepiness-positive versus the negative group. The sleepiness-positive group had higher MDS-UPDRS Part I and II but not III scores, and higher depression and autonomic dysfunction scores. Sleepiness was associated with a marginal reduction of A-beta (P = 0.05) but not alpha-synuclein spinal fluid levels in PD., Conclusions: This largest case control study demonstrates no difference in prevalence of excessive sleepiness in subjects with de novo untreated PD compared with healthy controls. The only clinical correlates of sleepiness were mood and autonomic dysfunction. Ongoing longitudinal analyses will be essential to further examine clinical and biological correlates of sleepiness in PD and specifically the role of dopaminergic therapy., (© 2015 International Parkinson and Movement Disorder Society.)
- Published
- 2015
- Full Text
- View/download PDF
27. Parkinson's Disease Genetic Loci in Rapid Eye Movement Sleep Behavior Disorder.
- Author
-
Gan-Or Z, Girard SL, Noreau A, Leblond CS, Gagnon JF, Arnulf I, Mirarchi C, Dauvilliers Y, Desautels A, Mitterling T, Cochen De Cock V, Frauscher B, Monaca C, Hogl B, Dion PA, Postuma RB, Montplaisir JY, and Rouleau GA
- Subjects
- Aged, Case-Control Studies, Female, Humans, Lysosomal Membrane Proteins genetics, Male, Middle Aged, Receptors, Scavenger genetics, Ubiquitin Thiolesterase genetics, tau Proteins genetics, Genetic Loci, Parkinson Disease genetics, Polymorphism, Single Nucleotide, REM Sleep Behavior Disorder genetics
- Abstract
Rapid eye movement (REM) sleep behavior disorder (RBD) is a prodromal condition for Parkinson's disease (PD) and other synucleinopathies, which often occurs many years before the onset of PD. We analyzed 261 RBD patients and 379 controls for nine PD-associated SNPs and examined their effects, first upon on RBD risk and second, on eventual progression to synucleinopathies in a prospective follow-up in a subset of patients. The SCARB2 rs6812193 (OR = 0.67, 95 % CI = 0.51-0.88, p = 0.004) and the MAPT rs12185268 (OR-0.43, 95 % CI-0.26-0.72, p = 0.001) were associated with RBD in different models. Kaplan-Meier survival analysis in a subset of RBD patients (n = 56), demonstrated that homozygous carriers of the USP25 rs2823357 SNP had progressed to synucleinopathies faster than others (log-rank p = 0.003, Breslow p = 0.005, Tarone-Ware p = 0.004). As a proof-of-concept study, these results suggest that RBD may be associated with at least a subset of PD-associated genes, and demonstrate that combining genetic and prodromal clinical data may help identifying individuals that are either more or less susceptible to develop synucleinopathies. More studies are necessary to replicate these results, and identify more genetic factors affecting progression from RBD to synucleinopathies.
- Published
- 2015
- Full Text
- View/download PDF
28. Tango for treatment of motor and non-motor manifestations in Parkinson's disease: a randomized control study.
- Author
-
Rios Romenets S, Anang J, Fereshtehnejad SM, Pelletier A, and Postuma R
- Subjects
- Dancing, Gait, Humans, Motor Skills, Parkinson Disease physiopathology, Pilot Projects, Postural Balance, Quality of Life, Treatment Outcome, Dance Therapy methods, Parkinson Disease therapy
- Abstract
Objective: To determine effects of Argentine tango on motor and non-motor manifestations of Parkinson's disease., Design: Randomized control trial., Participants: Forty patients with idiopathic Parkinson's disease., Setting: Movement disorder clinic and dance studio., Intervention: Two randomized groups: group (N=18) with 24 partnered tango classes, and control self-directed exercise group (N=15)., Main Outcomes Measures: The primary outcome was overall motor severity. Secondary outcomes included other motor measures, balance, cognition, fatigue, apathy, depression and quality of life., Results: On the primary intention-to-treat analysis there was no difference in motor severity between groups MDS-UPDRS-3 (1.6 vs.1.2-point reduction, p=0.85). Patient-rated clinical global impression of change did not differ (p=0.33), however examiner rating improved in favor of tango (p=0.02). Mini-BESTest improved in the tango group compared to controls (0.7±2.2 vs. -2.7±5.9, p=0.032). Among individual items, tango improved in both simple TUG time (-1.3±1.6s vs. 0.1±2.3, p=0.042) and TUG Dual Task score (0.4±0.9 vs. -0.2±0.4, p=0.012), with borderline improvement in walk with pivot turns (0.2±0.5 vs. -0.1±0.5, p=0.066). MoCa (0.4±1.6 vs. -0.6±1.5, p=0.080) and FSS (-3.6±10.5 vs. 2.5±6.2, p=0.057) showed a non-significant trend toward improvement in the tango group. Tango participants found the activity more enjoyable (p<0.001) and felt more "overall" treatment satisfaction (p<0.001). We found no significant differences in other outcomes or adverse events., Conclusion: Argentine tango can improve balance, and functional mobility, and may have modest benefits upon cognition and fatigue in Parkinson's disease. These findings must be confirmed in longer-term trials explicitly powered for cognition and fatigue., (Copyright © 2015 Elsevier Ltd. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
29. Predictors of dementia in Parkinson disease: a prospective cohort study.
- Author
-
Kawada T, Anang JB, and Postuma R
- Subjects
- Female, Humans, Male, Dementia epidemiology, Dementia etiology, Parkinson Disease complications, Parkinson Disease epidemiology
- Published
- 2015
- Full Text
- View/download PDF
30. Author response.
- Author
-
Anang JB and Postuma R
- Subjects
- Female, Humans, Male, Dementia epidemiology, Dementia etiology, Parkinson Disease complications, Parkinson Disease epidemiology
- Published
- 2015
31. Premotor and nonmotor features of Parkinson's disease.
- Author
-
Goldman JG and Postuma R
- Subjects
- Humans, Motor Activity, Olfaction Disorders etiology, Autonomic Nervous System Diseases etiology, Cognition Disorders etiology, Parkinson Disease complications, Sleep Wake Disorders etiology
- Abstract
Purpose of Review: This review highlights recent advances in premotor and nonmotor features in Parkinson's disease, focusing on these issues in the context of prodromal and early-stage Parkinson's disease., Recent Findings: Although Parkinson's disease patients experience a wide range of nonmotor symptoms throughout the disease course, studies demonstrate that nonmotor features are not solely a late manifestation. Indeed, disturbances of smell, sleep, mood, and gastrointestinal function may herald Parkinson's disease or related synucleinopathies and precede these neurodegenerative conditions by 5 or more years. In addition, other nonmotor symptoms such as cognitive impairment are now recognized in incident or de-novo Parkinson's disease cohorts. Many of these nonmotor features reflect disturbances in nondopaminergic systems and early involvement of peripheral and central nervous systems, including olfactory, enteric, and brainstem neurons as in Braak's proposed pathological staging of Parkinson's disease. Current research focuses on identifying potential biomarkers that may detect persons at risk for Parkinson's disease and permit early intervention with neuroprotective or disease-modifying therapeutics., Summary: Recent studies provide new insights into the frequency, pathophysiology, and importance of nonmotor features in Parkinson's disease as well as the recognition that these nonmotor symptoms occur in premotor, early, and later phases of Parkinson's disease.
- Published
- 2014
- Full Text
- View/download PDF
32. How do you diagnose appendicitis? An international evaluation of methods.
- Author
-
Alfraih Y, Postuma R, and Keijzer R
- Subjects
- Adolescent, Canada, Child, Cross-Sectional Studies, Diagnostic Imaging, Female, Humans, Male, Netherlands, Practice Patterns, Physicians', Saudi Arabia, Young Adult, Appendicitis diagnosis, Physicians statistics & numerical data
- Abstract
Introduction: Considerable variability exists in the diagnostic approach to acute appendicitis (in children), affecting both quality and costs of care. Interestingly, an international evaluation of what is commonly practiced today has not been performed. We aimed to document current practice patterns in the diagnosis of appendicitis in children and to determine whether a consensus exists in the workup of these patients among Canadian, Dutch, and Saudi Arabian pediatric surgeons., Methods: We performed a cross-sectional survey using a pre-designed, self-administered, 14-item survey. We sent the survey to participants via electronic mail., Results: In total, 83 responses were received and analyzed, yielding a response rate of 42%. The majority of respondents practiced at pediatric surgery centers with over 50 beds (58% of Canadian surgeons, 81% of Dutch surgeons, 93% of Saudi Arabian surgeons). The majority of Dutch surgeons had a preference for physical examination and radiological imaging as opposed to Canadian and Saudi Arabian surgeons who favored history and physical examination. Interestingly, only one of the surgeons surveyed used an appendicitis scoring system. Regarding history and physical examination, most respondents deemed migratory abdominal pain and localized RLQ tenderness to be most suggestive of appendicitis. Ultrasound was the most preferable imaging modality in acute appendicitis across all three countries., Conclusion: This study demonstrates that international pediatric surgeons vary substantially in the diagnostic workup of patients with appendicitis. Furthermore, there is a variability between common practice and the current evidence. We recommend that pediatric surgeons develop clinical practice guidelines that are based on consensus information (expert opinion) and the best available literature., (Copyright © 2013 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF
33. Validating chronic disease ascertainment algorithms for use in the Canadian longitudinal study on aging.
- Author
-
Oremus M, Postuma R, Griffith L, Balion C, Wolfson C, Kirkland S, Patterson C, Shannon HS, and Raina P
- Subjects
- Aged, Aged, 80 and over, Canada, Case-Control Studies, Female, Hand Joints, Humans, Longitudinal Studies, Male, Middle Aged, Osteoarthritis, Hip diagnosis, Osteoarthritis, Knee diagnosis, Prospective Studies, Reproducibility of Results, Sensitivity and Specificity, Surveys and Questionnaires, Algorithms, Asthma diagnosis, Diabetes Mellitus, Type 2 diagnosis, Myocardial Ischemia diagnosis, Osteoarthritis diagnosis, Parkinsonian Disorders diagnosis, Pulmonary Disease, Chronic Obstructive diagnosis
- Abstract
We validated seven chronic disease ascertainment algorithms for use in the Canadian Longitudinal Study on Aging. The algorithms pertained to diabetes mellitus type 2, parkinsonism, chronic airflow obstruction (CAO), hand osteoarthritis (OA), hip OA, knee OA, and ischemic heart disease. Our target recruitment was 20 cases and controls per disease; some cases were controls for unrelated diseases. Participants completed interviewer-administered disease symptom and medication use questionnaires. Diabetes cases and controls underwent fasting glucose testing; CAO cases and controls underwent spirometry testing. For each disease, the appropriate algorithm was used to classify participants' disease status (positive or negative for disease). We also calculated sensitivity and specificity using physician diagnosis as the reference standard. The final sample involved 176 participants recruited in three Canadian cities between 2009 and 2011. Most estimated sensitivities and specificities were 80 per cent or more, indicating that the seven algorithms correctly identified individuals with the target disease.
- Published
- 2013
- Full Text
- View/download PDF
34. Morbidities in rapid eye movement sleep behavior disorder.
- Author
-
Jennum P, Mayer G, Ju YE, and Postuma R
- Subjects
- Adult, Antidepressive Agents therapeutic use, Autoimmune Diseases epidemiology, Cognition Disorders epidemiology, Cognition Disorders physiopathology, Comorbidity, Depressive Disorder drug therapy, Depressive Disorder epidemiology, Female, Humans, Male, Morbidity, Muscle, Skeletal physiopathology, Narcolepsy physiopathology, Neurodegenerative Diseases physiopathology, Parkinson Disease physiopathology, REM Sleep Behavior Disorder physiopathology, Risk Factors, Narcolepsy epidemiology, Neurodegenerative Diseases epidemiology, Parkinson Disease epidemiology, REM Sleep Behavior Disorder epidemiology
- Abstract
Idiopathic rapid eye movement (REM) sleep behavior disorder (iRBD, RBD without any obvious comorbid major neurological disease), is strongly associated with numerous comorbid conditions. The most prominent is that with neurodegenerative disorders, especially synuclein-mediated disorders, above all Parkinson disease (PD). Idiopathic RBD is an important risk factor for the development of synucleinopathies. Comorbidity studies suggest that iRBD is associated with a number of other potential pre-motor manifestations of synucleinopathies such as, cognitive and olfactory impairment, reduced autonomic function, neuropsychiatric manifestations and sleep complaints. Furthermore, patients with PD and RBD may have worse prognosis in terms of impaired cognitive function and overall morbidity/mortality; in dementia, the presence of RBD is strongly associated with clinical hallmarks and pathological findings of dementia with Lewy bodies. These findings underline the progressive disease process, suggesting involvement of more brain regions in patients with a more advanced disease stage. RBD is also associated with narcolepsy, and it is likely that RBD associated with narcolepsy is a distinct subtype associated with different comorbidities. RBD is also associated with antidepressant medications, autoimmune conditions, and, in rare cases, brainstem lesions., (Copyright © 2012 Elsevier B.V. All rights reserved.)
- Published
- 2013
- Full Text
- View/download PDF
35. Rapid eye movement sleep behavior disorder: devising controlled active treatment studies for symptomatic and neuroprotective therapy--a consensus statement from the International Rapid Eye Movement Sleep Behavior Disorder Study Group.
- Author
-
Schenck CH, Montplaisir JY, Frauscher B, Hogl B, Gagnon JF, Postuma R, Sonka K, Jennum P, Partinen M, Arnulf I, Cochen de Cock V, Dauvilliers Y, Luppi PH, Heidbreder A, Mayer G, Sixel-Döring F, Trenkwalder C, Unger M, Young P, Wing YK, Ferini-Strambi L, Ferri R, Plazzi G, Zucconi M, Inoue Y, Iranzo A, Santamaria J, Bassetti C, Möller JC, Boeve BF, Lai YY, Pavlova M, Saper C, Schmidt P, Siegel JM, Singer C, St Louis E, Videnovic A, and Oertel W
- Subjects
- Clinical Trials as Topic methods, Clinical Trials as Topic standards, Clonazepam therapeutic use, Consensus, GABA Modulators therapeutic use, Humans, Melatonin therapeutic use, Parkinson Disease epidemiology, REM Sleep Behavior Disorder epidemiology, Risk Factors, Neuroprotective Agents therapeutic use, Parkinson Disease prevention & control, REM Sleep Behavior Disorder diagnosis, REM Sleep Behavior Disorder drug therapy
- Abstract
Objectives: We aimed to provide a consensus statement by the International Rapid Eye Movement Sleep Behavior Disorder Study Group (IRBD-SG) on devising controlled active treatment studies in rapid eye movement sleep behavior disorder (RBD) and devising studies of neuroprotection against Parkinson disease (PD) and related neurodegeneration in RBD., Methods: The consensus statement was generated during the fourth IRBD-SG symposium in Marburg, Germany in 2011. The IRBD-SG identified essential methodologic components for a randomized trial in RBD, including potential screening and diagnostic criteria, inclusion and exclusion criteria, primary and secondary outcomes for symptomatic therapy trials (particularly for melatonin and clonazepam), and potential primary and secondary outcomes for eventual trials with disease-modifying and neuroprotective agents. The latter trials are considered urgent, given the high conversion rate from idiopathic RBD (iRBD) to Parkinsonian disorders (i.e., PD, dementia with Lewy bodies [DLB], multiple system atrophy [MSA])., Results: Six inclusion criteria were identified for symptomatic therapy and neuroprotective trials: (1) diagnosis of RBD needs to satisfy the International Classification of Sleep Disorders, second edition, (ICSD-2) criteria; (2) minimum frequency of RBD episodes should preferably be ⩾2 times weekly to allow for assessment of change; (3) if the PD-RBD target population is included, it should be in the early stages of PD defined as Hoehn and Yahr stages 1-3 in Off (untreated); (4) iRBD patients with soft neurologic dysfunction and with operational criteria established by the consensus of study investigators; (5) patients with mild cognitive impairment (MCI); and (6) optimally treated comorbid OSA. Twenty-four exclusion criteria were identified. The primary outcome measure for RBD treatment trials was determined to be the Clinical Global Impression (CGI) efficacy index, consisting of a four-point scale with a four-point side-effect scale. Assessment of video-polysomnographic (vPSG) changes holds promise but is costly and needs further elaboration. Secondary outcome measures include sleep diaries; sleepiness scales; PD sleep scale 2 (PDSS-2); serial motor examinations; cognitive indices; mood and anxiety indices; assessment of frequency of falls, gait impairment, and apathy; fatigue severity scale; and actigraphy and customized bed alarm systems. Consensus also was established for evaluating the clinical and vPSG aspects of RBD. End points for neuroprotective trials in RBD, taking lessons from research in PD, should be focused on the ultimate goal of determining the performance of disease-modifying agents. To date no compound with convincing evidence of disease-modifying or neuroprotective efficacy has been identified in PD. Nevertheless, iRBD patients are considered ideal candidates for neuroprotective studies., Conclusions: The IRBD-SG provides an important platform for developing multinational collaborative studies on RBD such as on environmental risk factors for iRBD, as recently reported in a peer-reviewed journal article, and on controlled active treatment studies for symptomatic and neuroprotective therapy that emerged during the 2011 consensus conference in Marburg, Germany, as described in our report., (Copyright © 2013 Elsevier B.V. All rights reserved.)
- Published
- 2013
- Full Text
- View/download PDF
36. Doxepin and cognitive behavioural therapy for insomnia in patients with Parkinson's disease -- a randomized study.
- Author
-
Rios Romenets S, Creti L, Fichten C, Bailes S, Libman E, Pelletier A, and Postuma RB
- Subjects
- Actigraphy, Adult, Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Severity of Illness Index, Treatment Outcome, Antidepressive Agents, Tricyclic therapeutic use, Cognitive Behavioral Therapy methods, Doxepin therapeutic use, Parkinson Disease complications, Sleep Initiation and Maintenance Disorders drug therapy, Sleep Initiation and Maintenance Disorders etiology, Sleep Initiation and Maintenance Disorders rehabilitation
- Abstract
Introduction: Although a variety of pharmacologic and non-pharmacologic treatments are effective for insomnia in the general population, insomnia in Parkinson's disease differs in important ways and may need different treatments. No studies have conclusively demonstrated effective insomnia treatments in Parkinson's disease., Methods: We conducted a three-arm six-week randomized pilot study assessing non-pharmacologic treatment (cognitive behavioural therapy with bright light therapy) or doxepin (10 mg daily), compared to an inactive placebo in Parkinson's patients with insomnia. Sleep outcomes included insomnia scales, clinical global impression, sleep diaries and actigraphy. Secondary outcomes included motor severity, fatigue, depression and quality of life., Results: 18 patients were randomized, 6 to each group. Compared to placebo, doxepin improved the Insomnia Severity Index (-9 ± 5.4 vs. -2 ± 3.9, p = 0.03), the SCOPA-night score (-5.2 ± 1.5 vs. -2.3 ± 2.8, p = 0.049), the Pittsburgh Sleep Quality Index-sleep disturbances subscale (-0.5 ± 0.5 vs 0.2 ± 0.4, p = 0.02), and both patient and examiner-rated clinical global impression of change (1.7 ± 0.8 vs. 0.5 ± 0.8, p = 0.03 and 1.4 ± 0.5 vs. 0.3 ± 0.5, p = 0.003). On secondary outcomes doxepin reduced the fatigue severity scale (p = 0.02) and improved scores on the Montreal Cognitive Assessment (p = 0.007). Non-pharmacological treatment reduced the Insomnia Severity Index (-7.8 ± 3.8 vs. -2.0 ± 3.9, p = 0.03), and the examiner-reported clinical global impression of change (p = 0.006), but was associated with decline in Parkinson Disease Questionnaire-39. There were no changes in other primary and secondary outcomes, including actigraphy outcomes. Adverse events were comparable in all groups., Conclusion: Doxepin and non-pharmacologic treatment substantially improved insomnia in Parkinson's disease. These potential benefits must be replicated in a full confirmatory randomized controlled trial., (Crown Copyright © 2013. Published by Elsevier Ltd. All rights reserved.)
- Published
- 2013
- Full Text
- View/download PDF
37. Restless legs syndrome outside the blood-brain barrier--exacerbation by domperidone in Parkinson's disease.
- Author
-
Rios Romenets S, Dauvilliers Y, Cochen De Cock V, Carlander B, Bayard S, Galatas C, Wolfson C, and Postuma RB
- Subjects
- Aged, Domperidone therapeutic use, Dopamine Antagonists therapeutic use, Female, Humans, Male, Middle Aged, Parkinson Disease complications, Parkinson Disease physiopathology, Prevalence, Restless Legs Syndrome complications, Restless Legs Syndrome physiopathology, Treatment Outcome, Blood-Brain Barrier physiopathology, Domperidone adverse effects, Dopamine Antagonists adverse effects, Parkinson Disease drug therapy, Restless Legs Syndrome drug therapy
- Abstract
Introduction: Models of dopaminergic function in restless legs focus on central dopaminergic neurons. Domperidone, a peripheral dopamine blocker that cannot cross the blood-brain barrier, is commonly used in Parkinson's disease. After encountering a case of restless legs syndrome that dramatically worsened with domperidone, we assessed whether Parkinson's patients may have exacerbation of restless legs with domperidone., Methods: From two Parkinson's disease cohorts, we assessed restless legs prevalence according to standard criteria, in patients taking vs. not taking domperidone. Regression analysis was performed, adjusting for age, sex, disease duration, UPDRS, dopaminergic medications and other medications., Results: One hundred eighty four patients were assessed, of whom 46 (25%) had restless legs. Thirteen out of twenty seven (48%) patients on domperidone had restless legs compared to 33/157 (21%) without (p = 0.010). Other medications were not associated with restless legs., Conclusion: This unexpected finding suggests that dopaminergic neurons outside of the blood-brain barrier may be important in restless legs syndrome pathophysiology., (Copyright © 2012 Elsevier Ltd. All rights reserved.)
- Published
- 2013
- Full Text
- View/download PDF
38. Environmental risk factors for REM sleep behavior disorder: a multicenter case-control study.
- Author
-
Postuma RB, Montplaisir JY, Pelletier A, Dauvilliers Y, Oertel W, Iranzo A, Ferini-Strambi L, Arnulf I, Hogl B, Manni R, Miyamoto T, Mayer G, Stiasny-Kolster K, Puligheddu M, Ju Y, Jennum P, Sonka K, Santamaria J, Fantini ML, Zucconi M, Leu-Semenescu S, Frauscher B, Terzaghi M, Miyamoto M, Unger MM, Cochen De Cock V, and Wolfson C
- Subjects
- Aged, Alcohols adverse effects, Case-Control Studies, Coffee adverse effects, Confidence Intervals, Educational Status, Female, Humans, Male, Middle Aged, Occupations, Odds Ratio, Polysomnography, REM Sleep Behavior Disorder diagnosis, Risk Factors, Sensitivity and Specificity, Severity of Illness Index, Smoking, Surveys and Questionnaires, Tea adverse effects, Environment, Life Style, REM Sleep Behavior Disorder etiology
- Abstract
Objective: Idiopathic REM sleep behavior disorder is a parasomnia characterized by dream enactment and is commonly a prediagnostic sign of parkinsonism and dementia. Since risk factors have not been defined, we initiated a multicenter case-control study to assess environmental and lifestyle risk factors for REM sleep behavior disorder., Methods: Cases were patients with idiopathic REM sleep behavior disorder who were free of dementia and parkinsonism, recruited from 13 International REM Sleep Behavior Disorder Study Group centers. Controls were matched according to age and sex. Potential environmental and lifestyle risk factors were assessed via standardized questionnaire. Unconditional logistic regression adjusting for age, sex, and center was conducted to investigate the environmental factors., Results: A total of 694 participants (347 patients, 347 controls) were recruited. Among cases, mean age was 67.7 ± 9.6 years and 81.0% were male. Cases were more likely to smoke (ever smokers = 64.0% vs 55.5%, adjusted odds ratio [OR] = 1.43, p = 0.028). Caffeine and alcohol use were not different between cases and controls. Cases were more likely to report previous head injury (19.3% vs 12.7%, OR = 1.59, p = 0.037). Cases had fewer years of formal schooling (11.1 ± 4.4 years vs 12.7 ± 4.3, p < 0.001), and were more likely to report having worked as farmers (19.7% vs 12.5% OR = 1.67, p = 0.022) with borderline increase in welding (17.8% vs 12.1%, OR = 1.53, p = 0.063). Previous occupational pesticide exposure was more prevalent in cases than controls (11.8% vs 6.1%, OR = 2.16, p = 0.008)., Conclusions: Smoking, head injury, pesticide exposure, and farming are potential risk factors for idiopathic REM sleep behavior disorder.
- Published
- 2012
- Full Text
- View/download PDF
39. Canadian Guidelines on Parkinson's Disease.
- Author
-
Grimes D, Gordon J, Snelgrove B, Lim-Carter I, Fon E, Martin W, Wieler M, Suchowersky O, Rajput A, Lafontaine AL, Stoessl J, Moro E, Schoffer K, Miyasaki J, Hobson D, Mahmoudi M, Fox S, Postuma R, Kumar H, and Jog M
- Subjects
- Canada, Decision Trees, Humans, Patient Participation, Evidence-Based Medicine, Parkinson Disease diagnosis, Parkinson Disease therapy
- Published
- 2012
- Full Text
- View/download PDF
40. How does parkinsonism start? Prodromal parkinsonism motor changes in idiopathic REM sleep behaviour disorder.
- Author
-
Postuma RB, Lang AE, Gagnon JF, Pelletier A, and Montplaisir JY
- Subjects
- Age of Onset, Aged, Aged, 80 and over, Area Under Curve, Cohort Studies, Disease Progression, Female, Humans, Lewy Body Disease physiopathology, Linear Models, Male, Parkinson Disease epidemiology, Severity of Illness Index, Time Factors, Motor Activity physiology, Parkinson Disease diagnosis, Parkinson Disease physiopathology, REM Sleep Behavior Disorder physiopathology
- Abstract
Parkinsonism, as a gradually progressive disorder, has a prodromal interval during which neurodegeneration has begun but cardinal manifestations have not fully developed. A systematic direct assessment of this interval has never been performed. Since patients with idiopathic REM sleep behaviour disorder are at very high risk of parkinsonism, they provide a unique opportunity to observe directly the development of parkinsonism. Patients with idiopathic REM sleep behaviour disorder in an ongoing cohort study were evaluated annually with several quantitative motor measures, including the Unified Parkinson's Disease Rating Scale, Purdue Pegboard, alternate-tap test and timed up-and-go. Patients who developed parkinsonism were identified from this cohort and matched according to age to normal controls. Their results on motor testing from the preceding years were plotted, and then assessed with regression analysis, to determine when markers first deviated from normal values. Sensitivity and specificity of quantitative motor markers for diagnosing prodromal parkinsonism were assessed. Of 78 patients, 20 developed parkinsonism. On regression analysis, the Unified Parkinson's Disease Rating Scale first intersected normal values at an estimated 4.5 years before diagnosis. Voice and face akinesia intersected earliest (estimated prodromal interval = 9.8 years), followed by rigidity (4.4 years), gait abnormalities (4.4 years) and limb bradykinesia (4.2 years). Quantitative motor tests intersected normal values at longer prodromal intervals than subjective examination (Purdue Pegboard = 8.6 years, alternate-tap = 8.2, timed up-and-go = 6.3). Using Purdue Pegboard and the alternate-tap test, parkinsonism could be detected with 71-82% sensitivity and specificity 3 years before diagnosis, whereas a Unified Parkinson's Disease Rating Scale score >4 identified prodromal parkinsonism with 88% sensitivity and 94% specificity 2 years before diagnosis. Removal of action tremor scores improved sensitivity to 94% and specificity to 97% at 2 years before diagnosis (cut-off >3). Although distinction between conditions was often difficult, prodromal dementia with Lewy bodies appeared to have a slower progression than Parkinson's disease (prodromal interval = 6.0 versus 3.8 years). Using a cut-off of Unified Parkinson's Disease Rating Scale >3 (excluding action tremor), 25% of patients with 'still-idiopathic' REM sleep behaviour disorder demonstrated evidence of possible prodromal parkinsonism. Therefore, using direct assessment of motor examination before parkinsonism in a REM sleep behaviour disorder, we have estimated a prodromal interval of ∼4.5 years on the Unified Parkinson's Disease Rating Scale; other quantitative markers may detect parkinsonism earlier. Simple quantitative motor measures may be capable of reliably detecting parkinsonism, even before a clinical diagnosis can be made by experienced movement disorders neurologists.
- Published
- 2012
- Full Text
- View/download PDF
41. Suggested immobilization test for diagnosis of restless legs syndrome in Parkinson's disease.
- Author
-
De Cock VC, Bayard S, Yu H, Grini M, Carlander B, Postuma R, Charif M, and Dauvilliers Y
- Subjects
- Aged, Female, Humans, Male, Middle Aged, Parkinson Disease physiopathology, Polysomnography, Restless Legs Syndrome complications, Restless Legs Syndrome physiopathology, Sleep physiology, Immobilization methods, Parkinson Disease complications, Restless Legs Syndrome diagnosis
- Abstract
Diagnosis of restless leg syndrome (RLS) in Parkinson's disease (PD) is difficult because of clinical confounds. The suggested immobilization test (SIT) is validated for diagnosis of primary RLS. This study evaluated the usefulness of the SIT for diagnosis of RLS in PD. We compared SIT scores, as well as polysomnography measures in 50 patients with PD (25 with RLS, 25 without), 25 patients with primary RLS, and 25 age/sex matched controls. Mean leg discomfort score was increased in patients with PD and RLS compared to PD without RLS, and also in patients with primary RLS compared to controls. Leg discomfort was significantly higher at the end of the test in patients with RLS compared to patients without RLS. Intensity of leg discomfort was similar between patients with RLS, with or without PD. Using a mean leg discomfort cutoff of 11, we showed sensitivity of 91% and specificity of 72% for RLS diagnosis in PD during symptomatic time intervals. Periodic leg movements index during the SIT did not differ between groups. Periodic leg movements index during sleep and wakefulness was increased in patients with primary RLS compared to controls, but did not differ between patients with PD, with and without RLS. The sensory SIT is a simple test that may help diagnose RLS in patients with PD., (Copyright © 2012 Movement Disorder Society.)
- Published
- 2012
- Full Text
- View/download PDF
42. Dreaming in dementia--REM sleep behavior disorder and synucleinopathy.
- Author
-
Postuma R
- Subjects
- Female, Humans, Male, Lewy Body Disease complications, Lewy Body Disease pathology, REM Sleep Behavior Disorder classification, REM Sleep Behavior Disorder complications, REM Sleep Behavior Disorder pathology
- Published
- 2012
- Full Text
- View/download PDF
43. Validation of the non-motor symptoms questionnaire (NMS-Quest).
- Author
-
Romenets SR, Wolfson C, Galatas C, Pelletier A, Altman R, Wadup L, and Postuma RB
- Subjects
- Aged, Cross-Sectional Studies, Female, Humans, Male, Middle Aged, Sensitivity and Specificity, Neurologic Examination standards, Parkinson Disease diagnosis, Parkinson Disease physiopathology, Surveys and Questionnaires standards
- Abstract
Background: Although non-motor manifestations of Parkinson's disease are common and can cause severe disability, they are often under-recognized, leading to missed treatment opportunities. Screening tools for non-motor symptoms are urgently needed. Recently a 30-item screening Non Motor Symptoms Questionnaire was developed. Although some psychometric properties have been evaluated, sensitivity and specificity of the questionnaire have not been systematically assessed., Methods: Parkinson patients completed Non Motor Symptoms Questionnaire, then underwent a gold-standard clinical evaluation of non-motor symptoms and signs that included extensive standardized questionnaires, cognitive/behavioural assessment, and neurological examination to determine whether each manifestation was present or absent. The sensitivity and specificity of each non-motor symptom, in relation to the gold-standard were estimated., Results: For the 70 participants, the mean age was 66.7+/-9.3, 64% were men, and disease duration was 3.8+/-2.8 years. From the gold-standard evaluation, the prevalence of non-motor manifestations ranged from 8.7% (hallucinations) to 78.3% (nocturia). The mean sensitivity of all Non Motor Symptoms was 63.4%. This varied considerably among different manifestations, ranging from 24% (sleepiness, hyposmia) to 100% (diplopia). By restricting analysis to clinically significant non-motor problems (i.e. those serious enough to warrant treatment), the mean sensitivity increased to 71.8%. The specificity for most items was high, with an overall mean specificity of 88.5%., Conclusions: For many non-motor manifestations Non Motor Symptoms Questionnaire is an effective screen; however, for manifestations such as somnolence, olfactory loss and apathy, sensitivity is suboptimal. Overall, this questionnaire can be a useful clinical tool for screening non-motor problems in an office setting., (Crown Copyright © 2011. Published by Elsevier Ltd. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF
44. Cognition and olfaction in Parkinson's disease.
- Author
-
Postuma R and Gagnon JF
- Subjects
- Aged, Female, Humans, Male, Memory physiology, Middle Aged, Neuropsychological Tests, Psychomotor Performance physiology, Verbal Learning physiology, Cognition physiology, Parkinson Disease psychology, Smell physiology
- Published
- 2010
- Full Text
- View/download PDF
45. Clinical prediction of Parkinson's disease: planning for the age of neuroprotection.
- Author
-
Postuma RB, Gagnon JF, and Montplaisir J
- Subjects
- Biomarkers, Chronic Disease, Early Diagnosis, Humans, Predictive Value of Tests, Risk Factors, Neuroprotective Agents therapeutic use, Parkinson Disease diagnosis, Parkinson Disease drug therapy
- Abstract
As a chronic progressive disease, Parkinson's disease (PD) has a presymptomatic interval; that is, a period during which the pathological process has begun, but motor signs required for the clinical diagnosis are absent. The ability to identify this preclinical stage may be critical in the development and eventual use of neuroprotective therapy. Recently proposed staging systems of PD have suggested that degeneration may occur initially in areas outside the substantia nigra, suggesting that non-motor manifestations may be markers of presymptomatic PD. Decreased olfaction has recently been demonstrated to predict PD in prospective pathological studies, although the lead time may be relatively short, and the positive predictive value is low. Idiopathic RBD has a very high predictive value, with approximately 50% of affected individuals developing PD or dementia within 10 years. This implies that idiopathic RBD patients are ideal candidates to test potential preclinical markers. However, the specificity of symptom screens for RBD is not established, not all persons with PD develop RBD, and there are only limited ways to predict which RBD patients will develop PD. Other simple screens based upon autonomic symptoms, depression and personality changes, quantitative motor testing and other sleep disorders may also be useful markers, but have not been extensively tested. Other more expensive measures such as detailed autonomic testing, cardiac MIBG-scintigraphy, dopaminergic imaging and transcranial ultrasound may be especially useful in defining disease risk in those identified through primary screening.
- Published
- 2010
- Full Text
- View/download PDF
46. Transcranial ultrasound and olfaction in REM sleep behavior disorder: testing predictors of Parkinson's disease.
- Author
-
Postuma RB and Montplaisir J
- Subjects
- Predictive Value of Tests, Olfaction Disorders diagnosis, Olfaction Disorders epidemiology, Parkinson Disease diagnosis, Parkinson Disease epidemiology, REM Sleep Behavior Disorder diagnosis, Ultrasonography, Doppler, Transcranial methods
- Published
- 2010
- Full Text
- View/download PDF
47. Severity of REM atonia loss in idiopathic REM sleep behavior disorder predicts Parkinson disease.
- Author
-
Postuma RB, Gagnon JF, Rompré S, and Montplaisir JY
- Subjects
- Aged, Cohort Studies, Female, Follow-Up Studies, Humans, Longitudinal Studies, Male, Middle Aged, Parkinson Disease etiology, Polysomnography methods, Predictive Value of Tests, REM Sleep Behavior Disorder complications, Severity of Illness Index, Sleep, REM physiology, Parkinson Disease diagnosis, Parkinson Disease physiopathology, REM Sleep Behavior Disorder diagnosis, REM Sleep Behavior Disorder physiopathology
- Abstract
Background: Over 50% of persons with idiopathic REM sleep behavior disorder (RBD) will develop Parkinson disease (PD) or dementia. At present, there is no way to predict who will develop disease. Since polysomnography is performed in all patients with idiopathic RBD at diagnosis, there is an opportunity to analyze if baseline sleep variables predict eventual neurodegenerative disease., Methods: In a longitudinally studied cohort of patients with idiopathic RBD, we identified those who had developed neurodegenerative disease. These patients were matched by age, sex, and follow-up duration to patients with RBD who remained disease-free and to controls. Polysomnographic variables at baseline (i.e., before development of neurodegenerative disease) were compared between groups., Results: Twenty-six patients who developed neurodegenerative disease were included (PD 12, multiple system atrophy 1, dementia 13). The interval between polysomnogram and disease onset was 6.7 years, mean age was 69.5, and 81% were male. There were no differences between groups in sleep latency, sleep time, % stages 2-4, % REM sleep, or sleep efficiency. However, patients with idiopathic RBD who developed neurodegenerative disease had increased tonic chin EMG activity during REM sleep at baseline compared to those who remained disease-free (62.7 +/- 6.0% vs 41.0 +/- 6.0%, p = 0.020). This effect was seen only in patients who developed PD (72.9 +/- 6.0% vs 41.0 +/- 6.0%, p = 0.002), and not in those who developed dementia (54.3 +/- 10.3, p = 0.28). There was no difference in phasic submental REM EMG activity between groups., Conclusions: In patients with REM sleep behavior disorder initially free of neurodegenerative disease, the severity of REM atonia loss on baseline polysomnogram predicts the development of Parkinson disease.
- Published
- 2010
- Full Text
- View/download PDF
48. Markers of neurodegeneration in idiopathic rapid eye movement sleep behaviour disorder and Parkinson's disease.
- Author
-
Postuma RB, Gagnon JF, Vendette M, and Montplaisir JY
- Subjects
- Adult, Aged, Aged, 80 and over, Autonomic Nervous System Diseases diagnosis, Autonomic Nervous System Diseases etiology, Autonomic Nervous System Diseases physiopathology, Biomarkers, Diagnosis, Differential, Female, Humans, Hypotension diagnosis, Hypotension etiology, Hypotension physiopathology, Male, Middle Aged, Nerve Degeneration etiology, Nerve Degeneration physiopathology, Neurologic Examination, Neuropsychological Tests, Olfaction Disorders diagnosis, Olfaction Disorders etiology, Olfaction Disorders physiopathology, Parkinson Disease complications, Parkinson Disease physiopathology, Predictive Value of Tests, REM Sleep Behavior Disorder complications, REM Sleep Behavior Disorder physiopathology, Sex Characteristics, Vision Disorders diagnosis, Vision Disorders etiology, Vision Disorders physiopathology, Brain physiopathology, Nerve Degeneration diagnosis, Parkinson Disease diagnosis, REM Sleep Behavior Disorder diagnosis
- Abstract
Idiopathic rapid eye movement sleep behaviour disorder is an important risk factor in the development of Parkinson's disease. Numerous potential predictive markers of Parkinson's disease may present before motor symptoms emerge, but testing of these markers in rapid eye movement sleep behaviour disorder has been performed only in small studies. There has been no comparison of markers between patients with idiopathic rapid eye movement sleep behaviour disorder and Parkinson's disease, and between men and women. We evaluated an array of potential Parkinson's disease predictive markers in 159 patients; including 68 with idiopathic rapid eye movement sleep behaviour disorder, 36 controls, 34 Parkinson's patients with rapid eye movement sleep behaviour disorder and 21 Parkinson's patients without rapid eye movement sleep behaviour disorder. Compared with controls, patients with idiopathic rapid eye movement sleep behaviour disorder demonstrated substantial olfactory loss (P < 0.001). Olfaction was more impaired in Parkinson's disease than idiopathic rapid eye movement sleep behaviour disorder and did not differ between Parkinson's patients with, or without, rapid eye movement sleep behaviour disorder. Numerous measures of motor function including the Unified Parkinson Disease Rating Scale alternate tap, Purdue Peg Board and Timed 'Up and Go' were impaired in idiopathic rapid eye movement sleep behaviour disorder compared with controls (P < 0.01). All of these motor measures were worse with Parkinson's disease than with idiopathic rapid eye movement sleep behaviour disorder, regardless of rapid eye movement sleep behaviour disorder status. Autonomic symptoms and systolic blood pressure drop were impaired in patients with idiopathic rapid eye movement sleep behaviour disorder compared with controls (P = 0.003). Orthostatic abnormalities in Parkinson's disease were found in the group with rapid eye movement sleep behaviour disorder (P < 0.001). However, Parkinson's patients without rapid eye movement sleep behaviour disorder were not different than controls and had less impairment than those with idiopathic rapid eye movement sleep behaviour disorder (P = 0.004) and Parkinson's patients with rapid eye movement sleep behaviour disorder (P < 0.001). Colour vision was impaired in idiopathic rapid eye movement sleep behaviour disorder compared with controls (P < 0.001). However, only Parkinson's patients with rapid eye movement sleep behaviour disorder had abnormalities significantly different than controls (P < 0.001), and there were significant differences between Parkinson's patients with or without rapid eye movement sleep behaviour disorder (P < 0.04). Idiopathic rapid eye movement sleep behaviour disorder patients had slightly increased harm avoidance scores on personality testing (P = 0.04). Other than slightly better performances among women in the Purdue Peg Board, there was no difference in any measure between men and women, suggesting similar pathogenic processes underlying rapid eye movement sleep behaviour disorder. Patients with idiopathic rapid eye movement sleep behaviour disorder demonstrate abnormalities in numerous potential markers of neurodegenerative disease--these markers are heterogeneous, generally correlate with each other and occur equally in men and women. Although these abnormalities are usually intermediate between control values and Parkinson's patients, autonomic dysfunction and colour vision appear to be more linked to rapid eye movement sleep behaviour disorder status than Parkinson's disease, suggesting a unique pathophysiology of these abnormalities.
- Published
- 2009
- Full Text
- View/download PDF
49. Predicting Parkinson's disease - why, when, and how?
- Author
-
Postuma RB and Montplaisir J
- Subjects
- Autonomic Nervous System Diseases diagnosis, Autonomic Nervous System Diseases etiology, Brain Stem pathology, Brain Stem physiopathology, Depression diagnosis, Depression etiology, Disease Progression, Humans, Olfaction Disorders diagnosis, Olfaction Disorders etiology, Parkinson Disease complications, Parkinson Disease psychology, Personality, Predictive Value of Tests, Sleep Wake Disorders diagnosis, Sleep Wake Disorders etiology, Ultrasonography, Doppler, Transcranial methods, Vision Disorders diagnosis, Vision Disorders etiology, Parkinson Disease diagnosis
- Abstract
Parkinson's disease (PD) is a progressive disorder with a presymptomatic interval; that is, there is a period during which the pathologic process has begun, but motor signs required for the clinical diagnosis are absent. There is considerable interest in discovering markers to diagnose this preclinical stage. Current predictive marker development stems mainly from two principles; first, that pathologic processes occur in lower brainstem regions before substantia nigra involvement and second, that redundancy and compensatory responses cause symptoms to emerge only after advanced degeneration. Decreased olfaction has recently been demonstrated to predict PD in prospective pathologic studies, although the lead time may be relatively short and the positive predictive value and specificity are low. Screening patients for depression and personality changes, autonomic symptoms, subtle motor dysfunction on quantitative testing, sleepiness and insomnia are other potential simple markers. More invasive measures such as detailed autonomic testing, cardiac MIBG-scintigraphy, transcranial ultrasound, and dopaminergic functional imaging may be especially useful in those at high risk or for further defining risk in those identified through primary screening. Despite intriguing leads, direct testing of preclinical markers has been limited, mainly because there is no reliable way to identify preclinical disease. Idiopathic RBD is characterized by loss of normal atonia with REM sleep. Approximately 50% of affected individuals will develop PD or dementia within 10 years. This provides an unprecedented opportunity to test potential predictive markers before clinical disease onset. The results of marker testing in idiopathic RBD with its implications for disease prediction will be detailed.
- Published
- 2009
- Full Text
- View/download PDF
50. Quantifying the risk of neurodegenerative disease in idiopathic REM sleep behavior disorder.
- Author
-
Postuma RB, Gagnon JF, Vendette M, Fantini ML, Massicotte-Marquez J, and Montplaisir J
- Subjects
- Aged, Female, Follow-Up Studies, Humans, Lewy Body Disease epidemiology, Life Tables, Male, Middle Aged, Multiple System Atrophy epidemiology, Neurodegenerative Diseases psychology, Neuropsychological Tests, Polysomnography, Psychiatric Status Rating Scales, REM Sleep Behavior Disorder psychology, Risk, Survival Analysis, Dementia epidemiology, Neurodegenerative Diseases epidemiology, Neurodegenerative Diseases etiology, Parkinson Disease epidemiology, REM Sleep Behavior Disorder complications, REM Sleep Behavior Disorder epidemiology
- Abstract
Objective: Idiopathic REM sleep behavior disorder (RBD) is a potential preclinical marker for the development of neurodegenerative diseases, particularly Parkinson disease (PD) and Lewy body dementia. However, the long-term risk of developing neurodegeneration in patients with idiopathic RBD has not been established. Obtaining an accurate picture of this risk is essential for counseling patients and for development of potential neuroprotective therapies., Methods: We conducted a follow-up study of all patients seen at the sleep disorders laboratory at the Hôpital du Sacré Coeur with a diagnosis of idiopathic RBD. Diagnoses of parkinsonism and dementia were defined according to standard criteria. Survival curves were constructed to estimate the 5-, 10-, and 12-year risk of developing neurodegenerative disease., Results: Of 113 patients, 93 (82%) met inclusion criteria. The mean age of participants was 65.4 years and 75 patients (80.4%) were men. Over the follow-up period, 26/93 patients developed a neurodegenerative disorder. A total of 14 patients developed PD, 7 developed Lewy body dementia, 4 developed dementia that met clinical criteria for AD, and 1 developed multiple system atrophy. The estimated 5-year risk of neurodegenerative disease was 17.7%, the 10-year risk was 40.6%, and the 12-year risk was 52.4%., Conclusions: Although we have found a slightly lower risk than other reports, the risk of developing neurodegenerative disease in idiopathic REM sleep behavior disorder is substantial, with the majority of patients developing Parkinson disease and Lewy body dementia.
- Published
- 2009
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.